Does inhaled nitric oxide improve survival in operated congenital disease with severe pulmonary hypertension?
GROUND: The present study aimed to assess the impact of inhaled nitric oxide on survival following correction of congenital heart defects with residual pulmonary arterial hypertension. METHODS AND RESULTS: Inhaled nitric oxide was utilized for the management of residual pulmonary hypertension in 24 children following surgical correction of their underlying heart defects. Their ages ranged from 15 days to 14 months (median 5 months). Pulmonary artery hypertension was diagnosed either by direct pulmonary artery pressure monitoring or by echocardiography. Inhaled nitric oxide was used electively in 22 patients when the ratio of the mean pulmonary arterial pressure and mean systemic arterial pressure exceeded 0.5. In the remaining 2 patients, nitric oxide was used only to manage a pulmonary hypertensive crisis. Inhaled nitric oxide was also used a second time in 2 patients who developed delayed pulmonary hypertensive crisis. Twenty-two patients showed an initial response to therapy and the
Related Questions
- Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?
- Does inhaled nitric oxide improve survival in operated congenital disease with severe pulmonary hypertension?
- Does labetalol predispose to pulmonary edema in severe pregnancy-induced hypertensive disease?
